Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REDHILL BIOPHARMA LTD.

(RDHL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ REDHILL BIOPHARMA LTD.
11/24RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highligh..
PR
11/22REDHILL BIOPHARMA : UNDERWRITING AGREEMENT - Form 6-K
PU
11/15REDHILL BIOPHARMA : Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 ..
PU
11/09RedHill Biopharma to Present at H.C. Wainwright 7th Annual - Form 6-K
PU
11/09RedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German..
PR
11/08RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To ..
PU
11/08RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To ..
AQ
10/25REDHILL BIOPHARMA : Two new analyses evaluate pharmacological and clinical advantages of T..
PU
10/20REDHILL BIOPHARMA : to Present at the BIO-Europe 2021 Conference - Form 6-K
PU
10/20REDHILL BIOPHARMA : to Present at the BIO-Europe 2021 Conference
PR
10/18REDHILL BIOPHARMA : Announces Insider Buying - Form 6-K
PU
10/12REDHILL BIOPHARMA : Announces New U.S. Patent Covering - Form 6-K
PU
10/06REDHILL BIOPHARMA : Designed as a first-line option to address the high resistance of H. p..
PU
10/04REDHILL BIOPHARMA : A median four days earlier hospital discharge for opaganib-treated pat..
PU
09/23REDHILL BIOPHARMA : Patent litigation brought pursuant to The Drug Price Competition and P..
PU
09/14REDHILL BIOPHARMA : plans to hold a conference call to discuss the results in greater deta..
PU
09/14REDHILL BIOPHARMA : Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19..
PR
09/13REDHILL BIOPHARMA : RHB-107, a novel antiviral serine protease inhibitor targeting human c..
PU
09/07REDHILL BIOPHARMA : Antiviral activity and has already demonstrated strong inhibition agai..
PU
09/07REDHILL BIOPHARMA : Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
PR
09/07REDHILL BIOPHARMA : Movantik is the U.S. market-leading oral peripherally acting mu-opioid..
PU
09/07REDHILL BIOPHARMA : Presents Three New Analyses of Movantik Data at PAINWeek 2021
AQ
09/02REDHILL BIOPHARMA : to Present at H.C. Wainwright Annual Global Investment and Cantor Glob..
PU
09/02REDHILL BIOPHARMA : to Present at H.C. Wainwright Annual Global Investment and Cantor Glob..
PR
08/27REDHILL BIOPHARMA : The global 475-patient Phase 2/3 study with opaganib oral pill in hosp..
PU
08/26REDHILL BIOPHARMA : Reports Second Quarter 2021 Financial Results and Operational Highligh..
PR
08/26REDHILL BIOPHARMA : Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
PU
08/26REDHILL BIOPHARMA : Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
PR
08/23REDHILL BIOPHARMA : U.S. patents for opaganib combination for the treatment of Ebola virus..
PU
08/23REDHILL BIOPHARMA : Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and R..
PU
08/23REDHILL BIOPHARMA : Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and R..
PR
08/19REDHILL BIOPHARMA : to Host Second Quarter 2021 Financial Results and Operational Highligh..
PU
07/26REDHILL BIOPHARMA : (Translation of registrant's name into English) (Form 6-K)
PU
07/23REDHILL BIOPHARMA : Announces Settlement of Movantik Patent Litigation with Apotex
AQ
07/22REDHILL BIOPHARMA LTD :
AQ
07/22REDHILL BIOPHARMA : Announces Settlement of Movantik« Patent Litigation with Apotex (Form ..
PU
07/21REDHILL BIOPHARMA : 20 July, 2021 RedHill Biopharma Significantly Extends Unrestricted Com..
PU
07/20REDHILL BIOPHARMA : Designed as a first-line option to address the high resistance of H. p..
PU
07/19REDHILL BIOPHARMA : Patient follow-up completed for the 475-patient global Phase 2/3 study..
PU
07/19REDHILL BIOPHARMA : Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opagan..
PR
07/19REDHILL BIOPHARMA : 19 July, 2021 RedHill Biopharma Announces Last Patient Out for Phase 2..
PU
07/14REDHILL BIOPHARMA : Movantik Added as Unrestricted Preferred Brand to A Major National Com..
AQ
07/13REDHILL BIOPHARMA : Movantik is the U.S. market-leading oral peripherally acting mu-opioid..
PU
07/13REDHILL BIOPHARMA : Movantik« Added as Unrestricted Preferred Brand To A Major National Co..
PU
06/28REDHILL BIOPHARMA : Completion of opaganib's global fully enrolled 475-patient Phase 2/3 s..
PU
06/28REDHILL BIOPHARMA : Opaganib Inhibits COVID-19 Variants in Preclinical Study
PU
06/21REDHILL BIOPHARMA : Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID..
PR
06/21REDHILL BIOPHARMA : 21 June, 2021 RedHill Biopharma Announces Presentation of Positive Ora..
PU
06/10REDHILL BIOPHARMA : Notice of Annual General Meeting of Shareholders
PU
06/09REDHILL BIOPHARMA : to Present at the BIO Digital International Convention (Form 6-K)
PU
06/09REDHILL BIOPHARMA : to Present at the BIO Digital International Convention
PR
06/07REDHILL BIOPHARMA : Opaganib is uniquely positioned as a leading novel, dual-action, inves..
PU
06/07REDHILL BIOPHARMA : Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
PR
05/28REDHILL BIOPHARMA : Reports First Quarter 2021 Financial Results and Operational Highlight..
AQ
05/27REDHILL BIOPHARMA : (Translation of registrant's name into English) (Form 6-K)
PU
05/26REDHILL BIOPHARMA : Completion of Exchange Offer (Form 6-K)
PU
05/26REDHILL BIOPHARMA : Enrollment in opaganib's global Phase 2/3 study in hospitalized patien..
PU
05/26REDHILL BIOPHARMA : Receives Allowances for U.S. Patent Applications Covering Opaganib and..
PR
05/25REDHILL BIOPHARMA : 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of ..
PU
05/25REDHILL BIOPHARMA : Presents Analyses of Movantik Onset of Action and Symptom Improvement ..
AQ
05/24REDHILL BIOPHARMA : Two new analyses of Movantik« (naloxegol) data, from almost 900 patien..
PU
05/24REDHILL BIOPHARMA : Presents a New Travelers' Diarrhea Clinical Severity Classification To..
AQ
05/21REDHILL BIOPHARMA : Presents a New Travelers' Diarrhea Clinical Severity Classification To..
PU
05/21REDHILL BIOPHARMA : Aemcolo (rifamycin) is a non-systemic antibiotic whose delivery is tar..
PU
05/21REDHILL BIOPHARMA : Presents a New Travelers' Diarrhea Clinical Severity Classification To..
PR
05/20REDHILL BIOPHARMA : to Host First Quarter 2021 Financial Results and Operational Highlight..
PU
05/20REDHILL BIOPHARMA : to Host First Quarter 2021 Financial Results and Operational Highlight..
PR
04/09REDHILL BIOPHARMA : Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Un..
PR
03/26REDHILL BIOPHARMA : Announces Settlement of Movantik Patent Litigation with MSN Pharmaceut..
AQ
03/19ASTRAZENECA : RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Resul..
AQ
03/05REDHILL BIOPHARMA : Announces Closing of $35 Million Bought Deal Offering of American Depo..
AQ
03/03REDHILL BIOPHARMA : Increases Previously Announced Bought Deal to $35 Million of American ..
AQ
03/02REDHILL BIOPHARMA : Announces $10 Million Bought Deal Offering of American Depositary Shar..
AQ
02/24REDHILL BIOPHARMA : Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Stud..
AQ
02/19COSMO PHARMACEUTICALS N : RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuti..
AQ
1  2  3  4Next
Upcoming event on REDHILL BIOPHARMA LTD.
02/24/22